Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edemaPUBT·3 hours agoCHGCY-1.67%4519
Chugai licenses anti-dengue antibody AID351 to GSK in exclusive dealPUBT·Aug 17 at 09:33 PMCHGCY-1.67%4519
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology PipelineMarket Beat·Aug 16 at 03:01 PMRANI-0.11%CHGCY-1.67%
Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Decreases By 54.9%Market Beat·Aug 15 at 02:20 AMCHGCY-1.67%4519
Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatmentPUBT·Aug 14 at 01:32 AMCHGCY-1.67%4519
Chugai Pharmaceutical Stock And 2 Japan Picks Trading Below Cash Flow ValueSimplywall·Aug 13 at 10:50 AMMRAAY-1.57%CHGCY-1.67%
Phylo and Chugai collaborate to deploy AI platform in drug discoveryPharmaceutical Business Review·Aug 5 at 04:16 AMCHGCY-1.67%4519
Chugai seeks Japan approval for Enspryng to prevent MOGAD relapsesPUBT·Jul 31 at 01:32 AMCHGCY-1.67%4519
Chugai posts transcript of FY2026 Q2 financial results conference callPUBT·Jul 27 at 03:54 AMCHGCY-1.67%4519
Chugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure ConcernsSimplywall·Jul 26 at 12:13 PM4519
Chugai Pharmaceutical : Double-digit revenue and profit growth driven by strong sales and robust pipeline progressQuartr·Jul 24 at 02:01 AMCHGCY-1.67%4519
